VUG vs XBI

Vanguard Growth ETF vs SPDR S&P Biotech ETF

Quick take
  • VUG has the lower expense ratio at 0.03% vs 0.35% for XBI.
  • VUG pays a higher dividend yield (0.40%).

Side-by-side metrics

MetricVUGXBI
Expense ratio
Annual fee. Lower is better.
0.03%0.35%
Dividend yield
Trailing 12-month yield.
0.40%0.34%
AUM
Assets under management — bigger funds are typically more liquid.
$365.00B$8.30B
YTD return
5.76%12.92%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
1.221.09
P/E ratio
38.54
Last price
$86.05$133.66
Inception
Issuer
VanguardState Street

VUG top holdings

Top holdings · VUG
NVDANVIDIA Corp13.32%
AAPLApple Inc12.32%
MSFTMicrosoft Corp9.09%
GOOGLAlphabet Inc Class A5.54%
AMZNAmazon.com Inc4.59%
AVGOBroadcom Inc4.40%
GOOGAlphabet Inc Class C4.39%
METAMeta Platforms Inc Class A4.15%
TSLATesla Inc3.47%
LLYEli Lilly and Co2.60%
Sector breakdown · VUG
Real Estate1.1%
Consumer Cyclical12.6%
Basic Materials0.7%
Consumer Defensive1.7%
Technology52.6%
Communication Services16.5%
Financial Services4.6%
Industrials4.6%
Energy0.4%
Healthcare5.4%

XBI top holdings

Top holdings · XBI
APLSApellis Pharmaceuticals Inc1.87%
RVMDRevolution Medicines Inc Ordinary Shares1.65%
TVTXTravere Therapeutics Inc Ordinary Shares1.62%
ARWRArrowhead Pharmaceuticals Inc1.44%
TWSTTwist Bioscience Corp1.42%
SMMTSummit Therapeutics Inc Ordinary Shares1.40%
ALKSAlkermes PLC1.38%
TGTXTG Therapeutics Inc1.37%
MDGLMadrigal Pharmaceuticals Inc1.36%
BEAMBeam Therapeutics Inc1.32%
Sector breakdown · XBI
Financial Services0.2%
Healthcare99.8%

About VUG

VUG (Vanguard Growth ETF) is Large-cap US growth stocks. Managed by Vanguard, the fund carries $365.0B in assets under management, an expense ratio of 0.03%, a dividend yield of 0.40%. Its largest holding is NVIDIA Corp (NVDA), which represents 13.3% of the portfolio. Real Estate is the fund's largest sector exposure at 1.1%.

About XBI

XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.